RBC Capital Markets Reiterates Outperform, Raises PT On Express Scripts On Strong Start To Year

In a report published Tuesday, RBC Capital Markets analyst Frank G. Morgan reiterated an Outperform rating on

, and raised the price target from $82.00 to $87.00. In the report, RBC Capital Markets noted, "ESRX appears to be regaining momentum, with solid results and guidance, tight cost controls, and improving retention with a strong start to the 2016 selling season. While there was some concern about management's reluctance to confirm the long-term earnings growth outlook, we believe the continued strong cash flow and commitment to returning capital to shareholders provide downside risk protection, and the company's demonstrated ability to capitalize on emerging opportunities in specialty should help drive earnings growth. We maintain our Outperform rating." Express Scripts closed on Monday at $81.89.